Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 2
Submit an article Journal homepage
1,326
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation

Song Xuea Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
,
Yongping Zhanga Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
,
Fuhong Liua Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
,
Wenqiu Huanga Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
,
Ri Xub Beijing Bo Fu Rui Gene Diagnostics Co., Ltd, Beijing, China
&
Jingbo Wanga Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaCorrespondence[email protected]
Pages 478-482 | Received 29 May 2021, Accepted 16 Sep 2021, Published online: 05 Oct 2021

References

  • Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136–5145.
  • Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. J Clin Oncol. 2013;31(34):4333–4342.
  • Yang Q, Qian H, Jin Z, et al. SET-CAN fusion gene as poor prognosis predictor in adult T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(1):217–220.
  • Bazarbachi A, Labopin M, Angelucci E, et al. Haploidentical transplantation with Post-Transplantation cyclophosphamide for T cell acute lymphoblastic leukemia: a report from the European society for blood and marrow transplantation acute leukemia working party. Biol Blood Marrow Transplant. 2020;26(5):936–942.
  • Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
  • Chartron E, Theillet C, Guiu S, et al. Targeting homologous repair deficiency in breast and ovarian cancers: biological pathways, preclinical and clinical data. Crit Rev Oncol Hematol. 2019;133:58–73.
  • Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-Ribose) polymerase. J Pharmacol Exp Ther. 2015;353(3):446–457.
  • Zhang Y, Xue S, Liu F, et al. Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia. Leuk Res. 2020;91:106332.
  • Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239–254.e236.
  • Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.
  • Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110–120.
  • McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–8115.
  • Faraoni I, Giansanti M, Voso MT, et al. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochem Pharmacol. 2019;167:133–148.
  • Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.
  • Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16(3):211.
  • Parvin S, Ramirez-Labrada A, Aumann S, et al. LMO2 confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell. 2019;36(3):237–249.e6.
  • Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–1782.
  • Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366–375.
  • Popova T, Manié E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72(21):5454–5462.
  • Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5):478–488.
  • Vago L. Clonal evolution and immune evasion in posttransplantation relapses. Hematology Am Soc Hematol Educ Program. 2019;2019(1):610–616.
  • Makishima H, Maciejewski JP. Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res. 2011;17(12):3913–3923.
  • Pouliot GP, Degar J, Hinze L, et al. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLOS One. 2019;14(11):e0221288.
  • Schmidt MHM, Pearson CE. Disease-associated repeat instability and mismatch repair. DNA Repair. 2016;38:117–126.
  • Huang KW, Liu TC, Liang RY, et al. Structural basis for overhang excision and terminal unwinding of DNA duplexes by TREX1. PLOS Biol. 2018;16(5):e2005653.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.